Cargando…
Targeting oestrogen to kill the cancer but not the patient
The link between sex steroids and the development and growth of breast cancer has proved to be an invaluable clue for advances in the prevention and treatment of breast cancer. The identification of the oestrogen receptor (ER) not only allowed advances in the molecular endocrinology of oestrogen act...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409614/ https://www.ncbi.nlm.nih.gov/pubmed/14997187 http://dx.doi.org/10.1038/sj.bjc.6601627 |
_version_ | 1782155812113743872 |
---|---|
author | Lewis, J S Cheng, D Jordan, V C |
author_facet | Lewis, J S Cheng, D Jordan, V C |
author_sort | Lewis, J S |
collection | PubMed |
description | The link between sex steroids and the development and growth of breast cancer has proved to be an invaluable clue for advances in the prevention and treatment of breast cancer. The identification of the oestrogen receptor (ER) not only allowed advances in the molecular endocrinology of oestrogen action, but also provided a target for antioestrogenic therapeutic agents. However, the application of long-term or indefinite treatment regimens has consequences for the breast cancer. New forms of resistance, based upon enhanced cellular survival networks independent of ER and the suppression of apoptotic mechanisms, develop and then evolve. Remarkably, low concentrations of oestrogen collapse survival pathways and induce apoptosis in completely antihormonally refractory breast cancer. However, recurrent oestrogen-stimulated disease is again sensitive to antihormonal therapy. The novel reapplication of the ER as a therapeutic target for apoptosis is emerging as a new strategy for the long-term targeted maintenance treatment of breast cancer, and in formulating a targeted strategy for endocrine independent cancer. |
format | Text |
id | pubmed-2409614 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-24096142009-09-10 Targeting oestrogen to kill the cancer but not the patient Lewis, J S Cheng, D Jordan, V C Br J Cancer Minireview The link between sex steroids and the development and growth of breast cancer has proved to be an invaluable clue for advances in the prevention and treatment of breast cancer. The identification of the oestrogen receptor (ER) not only allowed advances in the molecular endocrinology of oestrogen action, but also provided a target for antioestrogenic therapeutic agents. However, the application of long-term or indefinite treatment regimens has consequences for the breast cancer. New forms of resistance, based upon enhanced cellular survival networks independent of ER and the suppression of apoptotic mechanisms, develop and then evolve. Remarkably, low concentrations of oestrogen collapse survival pathways and induce apoptosis in completely antihormonally refractory breast cancer. However, recurrent oestrogen-stimulated disease is again sensitive to antihormonal therapy. The novel reapplication of the ER as a therapeutic target for apoptosis is emerging as a new strategy for the long-term targeted maintenance treatment of breast cancer, and in formulating a targeted strategy for endocrine independent cancer. Nature Publishing Group 2004-03-08 2004-03-02 /pmc/articles/PMC2409614/ /pubmed/14997187 http://dx.doi.org/10.1038/sj.bjc.6601627 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Minireview Lewis, J S Cheng, D Jordan, V C Targeting oestrogen to kill the cancer but not the patient |
title | Targeting oestrogen to kill the cancer but not the patient |
title_full | Targeting oestrogen to kill the cancer but not the patient |
title_fullStr | Targeting oestrogen to kill the cancer but not the patient |
title_full_unstemmed | Targeting oestrogen to kill the cancer but not the patient |
title_short | Targeting oestrogen to kill the cancer but not the patient |
title_sort | targeting oestrogen to kill the cancer but not the patient |
topic | Minireview |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409614/ https://www.ncbi.nlm.nih.gov/pubmed/14997187 http://dx.doi.org/10.1038/sj.bjc.6601627 |
work_keys_str_mv | AT lewisjs targetingoestrogentokillthecancerbutnotthepatient AT chengd targetingoestrogentokillthecancerbutnotthepatient AT jordanvc targetingoestrogentokillthecancerbutnotthepatient |